203. Impact of an Infectious Diseases Fellow-Led Antimicrobial Stewardship Initiative in a Medical/Surgical ICU
Session: Poster Abstract Session: Antimicrobial Stewardship: Interventions to Improve Outcomes
Thursday, October 4, 2018
Room: S Poster Hall
  • Slide1.jpg (130.2 kB)
  • Background: Intensive care units carry the heaviest antibiotic burden within hospitals. Providing active and ongoing stewardship oversight in these areas is challenging for institutions with limited stewardship resources. The purpose of this study was to assess the impact of leveraging trainees, namely an infectious diseases fellow, in implementing a stewardship initiative in an intensive care unit.

    Methods: A single-center retrospective, quasi-experimental study assessed the impact of an infectious diseases fellow participating in daily medical rounds in a mixed medical and surgical ICU over a consecutive 4-month period. The ID fellow conducted physical examinations, reviewed antimicrobial therapy and de-escalated or discontinued antimicrobials when appropriate. Monthly days of therapy (DOT) per 1000 days at risk (DAR) for individual agents and total antimicrobial use were measured and compared for 4 months in the pre-, during-, and post-intervention phases.

    Results: Median overall antimicrobial use was similar between the pre-, during-, and post-intervention periods at 1089, 1100, and 1146 DOT/1000 DAR, respectively. For the 5 most commonly used drugs, reductions in DOT/1000 DAR were observed between the pre- and during-intervention groups for ampicillin/sulbactam (26%) and metronidazole (12%), while ceftriaxone, cefepime and vancomycin use was unchanged.

    Conclusion: While no change in median total antibiotic use was observed, a reduction in anti-anaerobic agent use noted, consistent with local efforts to reduce inappropriate antibiotic prescribing for aspiration pneumonitis. Actively involving medical residents and fellows in establishing evidenced-based approaches to antimicrobial stewardship is key to improving antibiotic utilization and minimizing the development of antimicrobial resistance.

    Ann Palmer, MD, Infectious Diseases, University of Connecticut, Hartford, CT, Ulysses Wu, MD, University of Connecticut, Hartford, CT, Prashant Grover, MD, Saint Francis Hospital, Hartord, CT and Dora Wiskirchen, PharmD, Saint Francis Hospital, Hartford, CT


    A. Palmer, None

    U. Wu, None

    P. Grover, None

    D. Wiskirchen, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.